Human Genome Sciences reports loss of $251m for 2006

Published



Rockville-based Human Genome Sciences, a biopharmaceutical firm, reported a total net loss of $251.2 million for 2006. “We substantially strengthened the company?s cash position in 2006,” Human Genome Sciences Senior Vice President and CFO Tim Barabe said in a statement. “Our unrestricted cash available for operations has grown to $702 million at the end of 2006 from $426 million at the end of 2005.” Revenues rose 35 percent in the fourth quarter of 2006. HGS is developing drugs to treat HIV, lupus, anthrax, cancer, rheumatoid arthritis and hepatitis C.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.